Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas, US Nonprofit Join Forces to Discover TB Drugs
October 19, 2017
- Takeda, HemoShear Link Up in Drug Discovery for Liver Diseases
October 19, 2017
- Daiichi Sankyo, Saitama Medical Univ. Launch AMED-Funded Research on FOP Therapy
October 19, 2017
- Daiichi Sankyo in Exosome Research Deal with NCC, Devices Makers
October 19, 2017
- Kyowa Kirin Eyes US Resubmission for Nouriast Next Year
October 18, 2017
- Bayer Files Long-Acting Hemophilia A Treatment in Japan
October 18, 2017
- Otsuka Seeks Japan Approval of Alcohol Dependence Med Nalmefene
October 18, 2017
- AZ’s Ex-Japan Chief Fredrickson Picked as Global Head of Oncology
October 18, 2017
- Durvalumab Improves PFS in Japanese NSCLC Patients
October 17, 2017
- Tagrisso Significantly Extends PFS in Japanese EGFRm NSCLC Patients
October 17, 2017
- Nobelpharma Plans to File Sakigake-Designated Topical Sirolimus; Application Expected Later this Month
October 17, 2017
- Japan’s Oncology Market Estimated to Reach Over 1.4 Trillion Yen in 2025: Fuji Keizai
October 17, 2017
- Ethical Drug Sales Up 2.2% in August, Keytruda Upbeat: Crecon
October 17, 2017
- Naldemedine Now Available in US: Shionogi
October 16, 2017
- Takeda Looks to House 3,000 Researchers at Shonan Innovation Park, Create Fund by March
October 16, 2017
- Eisai to Acquire Marketing Authorization for Kolbet from Toyama Chemical on Jan. 1
October 16, 2017
- Novartis Not to Conduct Additional Japan Study of Ribociclib, While PIb Study Underway in Asian Countries including Japan
October 16, 2017
- Sanwa Kagaku to Reduce 150 Jobs as Part of Suzuken Group’s SGA Cost Cutting Efforts
October 16, 2017
- JT Wins Japan Commercialization Rights for Calcifediol Extended-Release Capsules
October 16, 2017
- Kowa Wins Livalo Patent Suit against Towa
October 13, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…